Aiming for the cure in myeloma: Putting our best foot forward
N Bar, RS Firestone, SZ Usmani - Blood Reviews, 2023 - Elsevier
Frontline therapy for multiple myeloma (MM) is evolving to include novel combinations that
can achieve unprecedented deep response rates. Several treatment strategies exist, varying …
can achieve unprecedented deep response rates. Several treatment strategies exist, varying …
Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma
Multiple myeloma (MM) patients frequently attain a bone marrow (BM) minimal residual
disease (MRD) negativity status in response to treatment. We identified 568 patients who …
disease (MRD) negativity status in response to treatment. We identified 568 patients who …
Primary Plasma Cell Leukemia
S Al Hadidi - JAP Academy Journal, 2023 - journal.japacademy.org
Primary plasma cell leukemia (pPCL) is defined as the presence of 5% or more circulating
plasma cells on manual white blood cell differential count in newly diagnosed patients who …
plasma cells on manual white blood cell differential count in newly diagnosed patients who …
Expert perspective: Highlights on myeloma cell therapy from the American Society of Hematology Annual Meeting 2019
C Kunacheewa, EE Manasanch - Advances in Cell and Gene …, 2020 - Wiley Online Library
Autologous stem cell transplantation has been part of standard of treatment in multiple
myeloma for 2 decades. The data showed improving progression‐free survival and overall …
myeloma for 2 decades. The data showed improving progression‐free survival and overall …